Biosimilars
•11 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (11)
| Company | Market Cap | Price |
|---|---|---|
|
ABT
Abbott Laboratories
Abbott's biosimilars pipeline signals growth potential in biosimilar therapeutics, aligning with the Biosimilars investable theme.
|
$215.16B |
$123.64
-0.83%
|
|
AMGN
Amgen Inc.
Amgen maintains a significant Biosimilars portfolio with multiple launches since 2018.
|
$160.47B |
$298.45
+2.21%
|
|
VTRS
Viatris Inc.
Viatis pursues biosimilar opportunities alongside its generics portfolio.
|
$12.16B |
$10.36
|
|
RDY
Dr. Reddy's Laboratories Limited
Significant emphasis on biosimilar development and commercialization.
|
$11.09B |
$13.30
-1.12%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Amneal is expanding into biosimilars, a core diversification from traditional generics.
|
$3.39B |
$10.82
+8.20%
|
|
OGN
Organon & Co.
Biosimilars portfolio (Hadlima, Renflexis, Ontruzant, Tofidence) represents a major product line.
|
$1.75B |
$6.75
+2.66%
|
|
HROW
Harrow Health, Inc.
Strategic biosimilars portfolio in ophthalmology (BYOOVIZ, OPUVIZ) with Samsung Bioepis.
|
$1.39B |
$37.77
+0.55%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.20B |
$25.52
+3.49%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$397.76M |
$6.94
+1.76%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-111 and RT-105 include ustekinumab and adalimumab biosimilars, fitting the biosimilars category.
|
$126.59M |
$2.19
+50.69%
|
|
SCNX
Scienture Holdings, Inc.
SCN-106 is described as a potential biosimilar, fitting the Biosimilars investable theme.
|
$10.18M |
$0.78
+1.15%
|
Loading company comparison...
Loading industry trends...
Loading research report...
